Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07259317 · ClinicalTrials.gov registry record · Phase 2
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT07259317: Recruiting Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal, sponsored by Corcept Therapeutics.
NCT07259317 is a Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 60 participants, below the 94-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07259317, a Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
Primary Outcome
The percentage of patients with a DLT is used to estimate maximum tolerated dose (MTD), the most intense dose/schedule among those evaluated at which \<33% of patients experience DLT.
Conditions Studied
Interventions
- DRUG Relacorilant 150 mg once daily (QD)
- DRUG Nab-paclitaxel 100 mg/m^2
- DRUG Gemcitabine 1000 mg/m^2
Study Locations (4)
Arizona
- Site 02 - Scottsdale
California
- Site 04 - Los Angeles
Michigan
- Site 03 - Grand Rapids
Texas
- Site 01 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What NCT07259317 shows while recruiting
NCT07259317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 94-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (36% lower).
The record links to 2 conditions, with Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Relacorilant 150 mg once daily (QD) is the first listed.
NCT07259317 reports a single indexed study location in Arizona, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT07259317 about?
NCT07259317 is a clinical study titled "Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma". This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
What is the current status of trial NCT07259317?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-01-27. Estimated completion is 2027-07.
What conditions does trial NCT07259317 study?
This clinical trial studies the following conditions: Adenocarcinoma, Carcinoma, Pancreatic Ductal.
What interventions are being tested in trial NCT07259317?
The interventions under investigation include: Relacorilant 150 mg once daily (QD) (DRUG), Nab-paclitaxel 100 mg/m^2 (DRUG), Gemcitabine 1000 mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT07259317?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07259317 being conducted?
This trial has 4 study locations across Arizona, California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07259317's enrollment target sits among peer trials
60 11th of 26 higher than 16 of 26 other Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
COMPLETED · Phase 2
-
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI